GlassScriptPhysician profile
Samuel T Duncan
NPI 1063419810
$2,028.16
in general payments reported to CMS, 2019-2025
24 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.75 · 2020: $144 · 2021: $346 · 2022: $370 · 2023: $315 · 2024: $643 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,070.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $418.63 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Novo Nordisk INC | $283.84 | 2019-2024 | Wegovy |
| Oyster Point Pharma, INC. | $183.19 | 2022-2024 | Tyrvaya |
| Bausch & Lomb Americas INC. | $142.82 | 2024 | Miebo, Xiidra |
| Cequr Corporation | $137.86 | 2022-2023 | Cequr Simplicity |
| Pfizer INC. | $119.00 | 2023 | |
| Allergan, INC. | $85.02 | 2019-2021 | |
| Dexcom, INC. | $73.84 | 2022-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $70.97 | 2021 | |
| Azurity Pharmaceuticals, INC. | $67.47 | 2023-2025 | Edarbi, Edarbyclor, Edarbyclor |
| Lilly USA, LLC | $65.93 | 2019-2025 | Mounjaro |
| Horizon Therapeutics Plc | $57.16 | 2022-2023 | Tepezza |
| Exact Sciences Corporation | $56.32 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $56.12 | 2020-2021 | |
| Boston Scientific Corporation | $31.86 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $30.00 | 2021 | |
| Mallinckrodt Enterprises LLC | $29.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.20 | 2021 | |
| Alcon Vision LLC | $18.98 | 2024 | Simbrinza |
| Medtronic, INC. | $16.18 | 2021 | |
| Glaxosmithkline, LLC. | $14.55 | 2019 | |
| Xeris Pharmaceuticals, INC. | $14.51 | 2024 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $13.90 | 2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.